USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
TauRx Pharmaceuticals on Thursday said it has completed the final tranche of a $135 million equity financing launched in March to aid late-stage trials for its drugs to treat Alzheimer's and frontotemporal dementia. 8 October 2015
Specialty pharma company Pharmalink on Thursday said it is planning an initial public offering on Nasdaq Stockholm in 2016 to fund the development of its lead drug candidate to treat a kidney disease and that it has raised 100 million Swedish kronor ($12 million) from its investors to advance its research for its Nefecon (PL-56). 1 October 2015
MetaCure, the medical technology business focussed on diabetes devices, is looking at annual revenue of $20 million following the roll-out of its flagship product, the company’s founder Professor Shlomo Ben-Haim said in an exclusive interview to The Pharma Letter. 8 September 2015
Shield Therapeutics on Monday said it plans to raise up to £110 million ($169 million) via an initial public offering of its shares on the London Stock Exchange. 7 September 2015
Finnish biopharma company Faron has announced its intention to raise new funds through a placing and offer for subscriptions, and to apply for trading on the AIM market of the London Stock Exchange. 7 September 2015
USA-headquartered generics manufacturer Amneal has announced the creation of Amneal Biosciences, which will be a wholly-owned subsidiary of Amneal Pharmaceuticals. 26 August 2015
Google has announced it is segregating its life sciences unit into an independent company under the newly created parent group Alphabet. 24 August 2015
Privately held Presage Biosciences on Thursday said it has secured an investment from Japan’s largest drugmaker Takeda Pharmaceutical without disclosing any terms. 20 August 2015
Shares in Jordon-based drugmaker Hikma Pharma dropped nearly 2% in early trading Thursday on the London Stock Exchange as the company posted a 21% fall in first half 2015 earnings. 20 August 2015
Shares in India-based pharma company Cipla dropped over 4.5% on the Bombay Stock Exchange even as the company more than doubled first-quarter profit. 17 August 2015
Genmab reported a surge in first half 2015 operating income year-on-year driven by a one-time gain and lower expenses as revenue dropped 23%. 12 August 2015
India-based pharma company Zydus Cadila on Wednesday reported a 47% jump in first-quarter profit and announced a five-for-one stock split for its shares. 12 August 2015
Orexigen Therapeutics on Thursday said it has partnered with Kwang Dong Pharmaceutical to distribute weight loss medication in South Korea for an upfront payment of $7 million. 6 August 2015
German pharmaceutical firm Merck KGaA on Thursday posted a 13.2% rise in net profit for the second quarter boosted by favourable currency impact. 6 August 2015
Mallinckrodt on Tuesday posted third quarter (ended June 30) results ahead of estimates boosted by sales from the company’s recently acquired H.P. Acthar Gel (repository corticotropin injection) and Inomax (nitric oxide). 4 August 2015
Belgian pharmaceutical company UCB raised its outlook for 2015 as first-half sales beat estimates boosted by revenue from three major drugs. 3 August 2015
French drugmaker Ipsen on Friday posted a 7.9% rise in first-half 2015 sales, driven by a strong 12% growth of specialty care, especially due to its top-selling Somatuline (lanreotide), to treat gastrointestinal and pancreatic tumors. 31 July 2015
India-based Dr Reddy’s Laboratories posted a rise in first quarter revenue and profit boosted by growth in generics sales in the USA, Europe and India despite few new launches and currency devaluation in key emerging markets. 31 July 2015
Anglo-Swedish drug major AstraZeneca on Thursday posted a 2% rise in second-quarter revenue ahead of estimates as the company continues heavy investment in research and development of new product pipeline. 30 July 2015
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news